Clinical trials: Cesarean Section Rate
Labor Duration, Cesarean Section Rate
The MOBY Study: Efficacy of Birth Mobility
This randomized clinical trial investigates whether and how maternal mobility during labor influences birth outcomes in primiparous women.
- Conditions
- Labor Duration, Cesarean Section Rate, Maternal Mobility, Healthy
- Trial name
- MOBY (NCT07052331)
- Testing
- Birth Mobility System
- Where
- Switzerland
- Volunteers
- 714 people
- Sponsor
- Vibwife AG
Vaginal Delivery, Cesarean Section
Open Label Comparative Trial of Dinoprostone Plus or Minus Oxytocin Versus Oxytocin Alone in Cervical Ripening for Labor Induction
This is a comparative trial between oxytocin alone and dinoprostone for cervical ripening in unfavorable cervix pregnant women with 38 or more weeks of gestational age.
- Trial name
- SOFTNES (NCT01190163)
- Testing
- Dinoprostone, Oxytocin
- Where
- 4 sites in Brazil
- Volunteers
- 170 people
- Sponsor
- Ferring Pharmaceuticals
Cervical Ripening, Induction of Labor
Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)
The purpose of this study is to determine the pharmacokinetics (PK) of misoprostol acid for the MVI 200 in women requiring cervical ripening and induction of labor.
- Trial name
- NCT01283022
- Testing
- MVI 200
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ferring Pharmaceuticals
Reducing Time to Vaginal Delivery, Cervical Ripening
Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery
The purpose of this study is to determine whether the Misoprostol Vaginal Insert (MVI) 200 microgram (mcg) can decrease the time to vaginal delivery compared to the Dinoprostone Vaginal Insert (DVI) 10 milligram (mg) in pregnant…
- Conditions
- Reducing Time to Vaginal Delivery, Cervical Ripening, Induction of Labor
- Trial name
- EXPEDITE (NCT01127581)
- Testing
- MVI 200, Dinoprostone Vaginal Insert (DVI)
- Where
- 34 sites in United States
- Volunteers
- 1,358 people
- Sponsor
- Ferring Pharmaceuticals
Cervical Ripening, Induction of Labor
Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor
The purpose of this study is to assess the efficacy and safety of the 100, 150 and 200 mcg Misoprostol Vaginal Insert (MVI 100, MVI 150 and MVI 200) for women requiring cervical ripening and induction of labor.
- Trial name
- NCT00828711
- Testing
- MVI 100, MVI 150, MVI 200
- Where
- 11 sites in United States
- Volunteers
- 374 people
- Sponsor
- Ferring Pharmaceuticals